Results 121 to 130 of about 39,918 (251)

DiGeorge Syndrome Complicated by Secondary Antiphospholipid Syndrome Presenting With Vascular Thrombosis

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT DiGeorge syndrome (22q11.2 deletion syndrome) is a congenital disorder typically identified in infancy, but adult presentations may feature autoimmune and thrombotic complications. We report a 30‐year‐old woman with known DiGeorge syndrome who presented with progressive right lower extremity pain.
Aziz‐ur‐Rahman Khalid   +7 more
wiley   +1 more source

Apixaban

open access: yesItalian Journal of Medicine, 2013
Introduction: Thromboembolic events represent the final common mechanism in the pathogenesis of the most lethal vascular diseases in the developed countries (including acute coronary syndromes, ischemic stroke, deep vein thrombosis, and pulmonary ...
Gianluca Airoldi, Mauro Campanini
doaj   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 139-146, January 2026.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou   +12 more
wiley   +1 more source

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 46-62, January 2026.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik   +7 more
wiley   +1 more source

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 241-254, January 2026.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel   +13 more
wiley   +1 more source

A practical synthesis for the key intermediate (G) of Apixaban [PDF]

open access: green, 2023
Wen‐Wen Dong   +5 more
openalex   +1 more source

Evaluation of Two High‐Power Ablation Approaches in the Management of Typical Atrial Flutter: A Retrospective Study

open access: yesAnnals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.
To compare the acute and long‐term outcomes of high‐power ablation for typical atrial flutter using a 4‐mm irrigated catheter (4‐IC) versus an 8‐mm non‐irrigated catheter (8‐NIC). We conducted a retrospective cohort study of 215 patients who underwent cavotricuspid isthmus (CTI) ablation between January 2019 and December 2024.
Hina Pervaiz   +5 more
wiley   +1 more source

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 58-72, January 2026.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post   +4 more
wiley   +1 more source

Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center

open access: yesGynecologic Oncology Reports
Objective: A recent clinical trial demonstrated that the use of apixaban was safe and equal to enoxaparin (LMWH) in post-operative gynecologic oncology patients.
Victoria Diamond   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy